361.19
Bio Rad Laboratories Inc stock is traded at $361.19, with a volume of 207.47K.
It is down -0.25% in the last 24 hours and up +21.38% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$362.08
Open:
$364
24h Volume:
207.47K
Relative Volume:
0.58
Market Cap:
$9.66B
Revenue:
$2.59B
Net Income/Loss:
$168.80M
P/E Ratio:
59.46
EPS:
6.0748
Net Cash Flow:
$357.20M
1W Performance:
+5.48%
1M Performance:
+21.38%
6M Performance:
+40.78%
1Y Performance:
+25.78%
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BIO
Bio Rad Laboratories Inc
|
361.19 | 9.68B | 2.59B | 168.80M | 357.20M | 6.0748 |
|
ABT
Abbott Laboratories
|
111.27 | 191.92B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
341.09 | 133.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
90.58 | 116.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
51.69 | 74.52B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
92.56 | 53.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost? - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO) Upgraded to Hold at Zacks Research - MarketBeat
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
First Trust Advisors LP Has $424,000 Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance UK
Bio-Rad (BIO) Q2 2026 Earnings Call Transcript - AOL.com
Bio-Rad Laboratories (NYSE:BIO) Hits New 52-Week HighHere's What Happened - MarketBeat
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock - Yahoo Finance
Bio-Rad Laboratories (BIO) Stock Analysis: Exploring a Potentially Overvalued Healthcare Giant - DirectorsTalk Interviews
Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus - Yahoo Finance
Technical Reactions to BIO Trends in Macro Strategies - Stock Traders Daily
Assenagon Asset Management S.A. Acquires 85,393 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at 352.86 USD - Investing.com
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
US$329That's What Analysts Think Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Worth After These Results - 富途牛牛
Bio-Rad's FCPA Review Gets Picked Over at Trial - Law.com
Bio-Rad Laboratories, Inc. $BIO Shares Bought by California State Teachers Retirement System - marketbeat.com
Bio Rad Laboratories (BIO) Stock Jumps As ddPCR Progress Meets Flat Demand - Sahm
BIO-RAD LABORATORIES, INC. : WELLS FARGO RAISES TARGET PRICE TO $330 FROM $310 - webull.com
BIO Maintained by Citigroup -- Price Target Raised to $330 - GuruFocus
Is Bio-Rad Laboratories Inc (BIO) Overvalued After 4.5% Rally? G - GuruFocus
Citigroup Increases Bio-Rad Laboratories (NYSE:BIO) Price Target to $330.00 - MarketBeat
BIO Maintains Rating by Wells Fargo -- Price Target Raised to $3 - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Bio-Rad Laboratories (NYSE:BIO) Stock - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Sets New 52-Week High on Earnings Beat - marketbeat.com
Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BIO SWOT Analysis: Financial Resilience Amidst Market Challenges Revealed in 10-Q Filing - GuruFocus
AUG 04 (REUTERS)BIO-RAD Q2 EPS USD 13.85. - Moomoo
Amundi Has $10.81 Million Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Earnings: Modest Sequential Improvement, but Full-Year Guidance Ranges Remain Wide - Morningstar
Bio-Rad Laboratories Inc (BIO) (Q2 2026) Earnings Call Highlights: Digital PCR Surges 20%+ as ... By GuruFocus - Investing.com Canada
BIO Looks 4.8% Overvalued on GF Value™ Amid Restructuring Plans - GuruFocus
Bio-Rad Laboratories Q2 Earnings Call Highlights - MarketBeat
Bio-Rad: Q2 Earnings Snapshot - Barchart.com
Is Bio-Rad Laboratories Inc (BIO) Overvalued After Q2 Earnings B - GuruFocus
Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates - finance.yahoo.com
Bio-Rad Laboratories, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Bio-Rad tops Q2 2026 estimates, shares fall after hours - Investing.com
BIO Looks 4.8% Overvalued on GF Value™ as Growth Momentum Shines - GuruFocus
BIO Looks 4.8% Overvalued on GF Value™ as Market Weighs 2026 Gui - GuruFocus
Bio-Rad Laboratories Q2 Adjusted Earnings Rise, Revenue Falls - marketscreener.com
Q2 2026 Bio Rad Laboratories Inc Earnings Call Transcript - GuruFocus
Bio-Rad Laboratories (BIO) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Bio-Rad Laboratories (NYSE:BIO) Releases Earnings Results, Beats Estimates By $0.87 EPS - MarketBeat
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q2 Revenue $651.0M, vs. FactSet Est of $624.0M - marketscreener.com
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Posts Q2 Adjusted EPS $2.62 per Share, vs. FactSet Est of $1.75 - marketscreener.com
BIO-RAD LABORATORIES, INC. 2Q 2026: Revenue $651M, EPS $13.85— 10-Q Summary - TradingView
Bio-Rad Laboratories (NYSE: BIO) Q2 profit offset by H1 fair-value losses - Stock Titan
Press Release: Bio-Rad Reports Second-Quarter 2026 Financial Results - Moomoo
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):